Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to understand the following safety related particulars associated with the use of Pariet Tablet 5 milligram (mg) to prevent gastric and duodenal ulcer from low dose aspirin administration of 100 mg or less daily in participants with a history of gastric and duodenal ulcer: 1. Serious adverse events (SAEs) and adverse drug reactions (ADRs) 2. Unexpected adverse events (AEs) and ADRs not reflected in the precautions for use 3. Known ADRs 4. Non-serious ADRs 5. Other safety and efficacy related information.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05208268
Study type Observational
Source Eisai Inc.
Contact Jina JiEun Kim
Phone +82-10-9708-0744
Email [email protected]
Status Recruiting
Start date July 23, 2020
Completion date November 11, 2022

See also
  Status Clinical Trial Phase
Completed NCT01435525 - Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation N/A
Completed NCT00284908 - Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers Phase 1
Completed NCT00952978 - Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3) Phase 3
Completed NCT01964131 - BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects Phase 1
Completed NCT01452724 - Efficacy and Safety of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Duodenal Ulcer Phase 3
Recruiting NCT01037491 - Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets N/A
Completed NCT00595517 - Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer Phase 3
Completed NCT00953381 - Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2) Phase 2
Recruiting NCT05010954 - Efficacy and Safety of LXI-15028 Comparing With Lansoprazole in the Treatment of Duodenal Ulcer Phase 3
Completed NCT01199536 - Helicobacter Pylori Eradication Treatment in Patients With Duodenal Ulcers N/A
Recruiting NCT03057171 - A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA
Completed NCT01568398 - A Unblinded Study of TAK-438 (20 mg) for Prevention of Recurrence of Gastric or Duodenal Ulcer During Long-Term Low-Dose Aspirin Therapy Phase 3
Terminated NCT00762359 - A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers Phase 3
Completed NCT02423187 - Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin
Completed NCT00543868 - MK0782 + Low-Dose Aspirin 7-Day Erosion Endoscopy Study (0782-001) Phase 2
Active, not recruiting NCT03553563 - A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer Phase 3
Active, not recruiting NCT04702542 - To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children. N/A
Completed NCT00132171 - Helicobacter Pylori Eradication With a New Sequential Treatment Phase 3
Completed NCT00173953 - Lymphocytic Subsets and Cytokine Production With H. Pylori Infection N/A
Recruiting NCT00197470 - Cytokine Gene Polymorphisms in Gastric Diseases N/A